Viewing data from:

ZONISAMIDE

ANDA

ZONISAMIDE | A077645 | AUROBINDO PHARMA LTD

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: ZONEGRAN(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$0.1078

per ea

Lowest NADAC/Unit

$0.0597

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
59651038001ZONISAMIDE 100 MG CAPSULE	$0.1078	EA	Generic	—	2026-06-17
59651037901ZONISAMIDE 50 MG CAPSULE	$0.0950	EA	Generic	—	2026-06-17
59651037801ZONISAMIDE 25 MG CAPSULE	$0.0597	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain13 active DMFs8 inactive

11 active API suppliers hold Drug Master Files for this ingredient.

SUMITOMO PHARMA CO LTDZONISAMIDE DRUG SUBSTANCE

DMF 121981996

DIPHARMA FRANCIS SRLZONISAMIDE

DMF 173032004

ALIVUS LIFE SCIENCES LTDZONISAMIDE

DMF 179452004

WOCKHARDT LTDZONISAMIDE USP

DMF 180592005

SUN PHARMACEUTICAL INDUSTRIES LTDZONISAMIDE USP

DMF 181912005

ZYDUS LIFESCIENCES LTDZONISAMIDE

DMF 182072005

HETERO LABS LTDZONISAMIDE

DMF 184882005

MAITHRI DRUGS PRIVATE LTDZONISAMIDE USP

DMF 310092016

COHANCE LIFESCIENCES LTDZONISAMIDE USP

DMF 312982017

ALIVUS LIFE SCIENCES LTDZONISAMIDE USP (D270 PROCESS)

DMF 319732017

COHANCE LIFESCIENCES LTDZONISAMIDE USP

DMF 332562018

EMNAR PHARMA PRIVATE LTDZONISAMIDE USP

DMF 385242023

UNICHEM LABORATORIES LTDZONISAMIDE USP

DMF 402932024

PERRIGO API LTDInactiveZONISAMIDE

DMF 170272003

PROCOS SPAInactiveZONISAMIDE

DMF 172542004

JUZEN CHEMICAL CORPInactiveZONISAMIDE

DMF 176612004

MYLAN LABORATORIES LTDInactiveZONISAMIDE

DMF 179752005

DR REDDYS LABORATORIES LTDInactiveZONISAMIDE

DMF 181032005

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveZONISAMIDE

DMF 181972005

APOTEX PHARMACHEM INCInactiveZONISAMIDE

DMF 182032005

BACHEM SAInactiveZONISAMIDE

DMF 222762008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Dec 28, 2005	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — 100MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Dec 22, 2005

No patent or exclusivity listings for this strength.

#002 — 25MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Sep 29, 2006

#003 — 50MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Sep 29, 2006